Department of Obstetrics and Gynaecology, Jessop Wing, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2SF, UK.
Eur J Obstet Gynecol Reprod Biol. 2012 Feb;160(2):147-50. doi: 10.1016/j.ejogrb.2011.11.018. Epub 2011 Dec 3.
The aim of the study was to compare maternal and neonatal outcomes in women with gestational diabetes mellitus (GDM) treated with metformin in addition to the dietary and lifestyle advice versus those treated traditionally with dietary and lifestyle advice only.
A retrospective study of singleton pregnancies in women with GDM delivered between January 2008 to June 2010 (n=592) at the Jessop Wing, Royal Hallamshre Hospital, UK. Introduction of metformin in August 2008 led to two comparable groups, those women receiving metformin, lifestyle advice (including dietary advice) ± supplementary insulin and those women receiving lifestyle advice (including dietary advice) ± supplementary insulin. Two hundred and ninety three women were treated with metformin and lifestyle advice and remaining 299 with lifestyle advice only. Supplementary insulin was used in both the groups if needed. Outcomes were analyzed using the chi-squared and t-tests.
There were no significant differences in baseline maternal characteristics between the two groups. Metformin was tolerated throughout the pregnancy by 90% of the women in the metformin+lifestyle advice group. Supplementary insulin was required by 21% in the metformin+lifestyle advice group compared to 37% in the lifestyle advice group (OR 0.46; 95% CI 0.32-0.66). Women in the metformin group had a significantly lower incidence of macrosomia (birth weight>4kg) (8.2% vs. 14.3% (OR 0.56; 95% CI 0.33-0.99)), as well as birth weight >90th centile (14.8% vs. 23.7% (OR 0.56; 95% CI 0.37-0.85)). There were no significant differences in maternal outcome measures between the groups. No serious maternal or neonatal adverse events were observed with the use of metformin.
Metformin is safe and effective in the treatment of GDM in our experience. It is well tolerated and reduces the requirement for supplementary insulin. Women treated with metformin had a significantly lower incidence of macrosomic and large for gestational age neonates as well as a reduced caesarean section rate.
本研究旨在比较在饮食和生活方式建议的基础上加用二甲双胍治疗与单纯接受饮食和生活方式建议治疗的妊娠糖尿病(GDM)女性的母婴结局。
对 2008 年 1 月至 2010 年 6 月在英国皇家哈利郡医院杰索普翼楼分娩的 GDM 单胎妊娠女性(n=592)进行回顾性研究。2008 年 8 月开始使用二甲双胍,由此分为两组:接受二甲双胍+生活方式建议(包括饮食建议)+补充胰岛素的女性和接受生活方式建议(包括饮食建议)+补充胰岛素的女性。293 名女性接受二甲双胍+生活方式建议治疗,299 名女性仅接受生活方式建议治疗。如果需要,两组均使用补充胰岛素。使用卡方检验和 t 检验分析结局。
两组女性的基线母体特征无显著差异。在接受二甲双胍+生活方式建议治疗的女性中,90%能够耐受整个孕期的二甲双胍。二甲双胍+生活方式建议组需要补充胰岛素的女性占 21%,而生活方式建议组需要补充胰岛素的女性占 37%(OR 0.46;95%CI 0.32-0.66)。二甲双胍组女性巨大儿(出生体重>4kg)的发生率显著降低(8.2% vs. 14.3%(OR 0.56;95%CI 0.33-0.99)),出生体重>第 90 百分位数的发生率也显著降低(14.8% vs. 23.7%(OR 0.56;95%CI 0.37-0.85))。两组女性的母体结局测量值无显著差异。在使用二甲双胍时,未观察到严重的母体或新生儿不良事件。
根据我们的经验,二甲双胍治疗 GDM 安全有效。它耐受性良好,可减少对补充胰岛素的需求。接受二甲双胍治疗的女性巨大儿和大于胎龄儿的发生率显著降低,剖宫产率也降低。